Beneficial effects of nalmefene augmentation in neuroleptic-stabilized schizophrenic patients
It was postulated that chronic blockade of the opioid system in neuroleptic-stabilized schizophrenic patients would have a beneficial behavioral effect. Eleven neuroleptic-stabilized psychotic inpatients received augmentation with nalmefene for an average of 36.7 days in a double-blind placebo-contr...
Gespeichert in:
| Veröffentlicht in: | Neuropsychopharmacology (New York, N.Y.) N.Y.), 1993-09, Vol.9 (2), p.111-115 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 115 |
|---|---|
| container_issue | 2 |
| container_start_page | 111 |
| container_title | Neuropsychopharmacology (New York, N.Y.) |
| container_volume | 9 |
| creator | RAPAPORT, M. H WOLKOWITZ, O KELSOE, J. R PATO, C KONICKI, P. E PICKAR, D |
| description | It was postulated that chronic blockade of the opioid system in neuroleptic-stabilized schizophrenic patients would have a beneficial behavioral effect. Eleven neuroleptic-stabilized psychotic inpatients received augmentation with nalmefene for an average of 36.7 days in a double-blind placebo-controlled study. The patients exhibited significant reductions in Bunney-Hamburg psychosis ratings and the Brief Psychiatric Rating Scale thinking disturbance subscale during the augmentation period. This study presents preliminary data supporting the hypothesis that chronic augmentation of neuroleptic-stabilized schizophrenic patients with opiate antagonists is beneficial. |
| doi_str_mv | 10.1038/npp.1993.49 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76018035</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76018035</sourcerecordid><originalsourceid>FETCH-LOGICAL-c313t-bb29da302078d04362c216ef09e46ba49e18871f91176937a88ef487bb767e823</originalsourceid><addsrcrecordid>eNo9kL1PwzAQRy0EKqUwMSNlQCwoxRe7sT1CxZdUiQWkLshynDM1SpwQJwP960nViumG9-43PEIugc6BMnkX2nYOSrE5V0dkCoLTNGd8fUymVCqWAmPrU3IW4zelsBC5nJCJBLoQik7J5wMGdN56UyXoHNo-Jo1LgqlqdCNKzPBVY-hN75uQ-JAEHLqmwrb3No29KXzlt1gm0W78tmk3HQZvk3bUx6d4Tk6cqSJeHO6MfDw9vi9f0tXb8-vyfpVaBqxPiyJTpWE0o0KWlLM8sxnk6KhCnheGKwQpBTgFIHLFhJESHZeiKEQuUGZsRm72u23X_AwYe137aLGqTMBmiFrkFCRli1G83Yu2a2Ls0Om287XpfjVQvYupx5h6F1NzNdpXh9mhqLH8dw_1Rn594CZaU7nOBOvjv8YkZJAJ9gccyX3a</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76018035</pqid></control><display><type>article</type><title>Beneficial effects of nalmefene augmentation in neuroleptic-stabilized schizophrenic patients</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>SpringerLink Journals - AutoHoldings</source><creator>RAPAPORT, M. H ; WOLKOWITZ, O ; KELSOE, J. R ; PATO, C ; KONICKI, P. E ; PICKAR, D</creator><creatorcontrib>RAPAPORT, M. H ; WOLKOWITZ, O ; KELSOE, J. R ; PATO, C ; KONICKI, P. E ; PICKAR, D</creatorcontrib><description>It was postulated that chronic blockade of the opioid system in neuroleptic-stabilized schizophrenic patients would have a beneficial behavioral effect. Eleven neuroleptic-stabilized psychotic inpatients received augmentation with nalmefene for an average of 36.7 days in a double-blind placebo-controlled study. The patients exhibited significant reductions in Bunney-Hamburg psychosis ratings and the Brief Psychiatric Rating Scale thinking disturbance subscale during the augmentation period. This study presents preliminary data supporting the hypothesis that chronic augmentation of neuroleptic-stabilized schizophrenic patients with opiate antagonists is beneficial.</description><identifier>ISSN: 0893-133X</identifier><identifier>EISSN: 1740-634X</identifier><identifier>DOI: 10.1038/npp.1993.49</identifier><identifier>PMID: 8105790</identifier><identifier>CODEN: NEROEW</identifier><language>eng</language><publisher>New York, NY: Nature Publishing</publisher><subject>Adolescent ; Adult ; Antipsychotic Agents - therapeutic use ; Biological and medical sciences ; Double-Blind Method ; Drug Therapy, Combination ; Female ; Homovanillic Acid - blood ; Humans ; Hydrocortisone - blood ; Male ; Medical sciences ; Methoxyhydroxyphenylglycol - blood ; Naltrexone - analogs & derivatives ; Naltrexone - therapeutic use ; Narcotic Antagonists - therapeutic use ; Neuropharmacology ; Pharmacology. Drug treatments ; Prolactin - blood ; Psychiatric Status Rating Scales ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Schizophrenia - drug therapy ; Schizophrenic Psychology</subject><ispartof>Neuropsychopharmacology (New York, N.Y.), 1993-09, Vol.9 (2), p.111-115</ispartof><rights>1994 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c313t-bb29da302078d04362c216ef09e46ba49e18871f91176937a88ef487bb767e823</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,776,780,785,786,23909,23910,25118,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3812127$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8105790$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>RAPAPORT, M. H</creatorcontrib><creatorcontrib>WOLKOWITZ, O</creatorcontrib><creatorcontrib>KELSOE, J. R</creatorcontrib><creatorcontrib>PATO, C</creatorcontrib><creatorcontrib>KONICKI, P. E</creatorcontrib><creatorcontrib>PICKAR, D</creatorcontrib><title>Beneficial effects of nalmefene augmentation in neuroleptic-stabilized schizophrenic patients</title><title>Neuropsychopharmacology (New York, N.Y.)</title><addtitle>Neuropsychopharmacology</addtitle><description>It was postulated that chronic blockade of the opioid system in neuroleptic-stabilized schizophrenic patients would have a beneficial behavioral effect. Eleven neuroleptic-stabilized psychotic inpatients received augmentation with nalmefene for an average of 36.7 days in a double-blind placebo-controlled study. The patients exhibited significant reductions in Bunney-Hamburg psychosis ratings and the Brief Psychiatric Rating Scale thinking disturbance subscale during the augmentation period. This study presents preliminary data supporting the hypothesis that chronic augmentation of neuroleptic-stabilized schizophrenic patients with opiate antagonists is beneficial.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Double-Blind Method</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Homovanillic Acid - blood</subject><subject>Humans</subject><subject>Hydrocortisone - blood</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Methoxyhydroxyphenylglycol - blood</subject><subject>Naltrexone - analogs & derivatives</subject><subject>Naltrexone - therapeutic use</subject><subject>Narcotic Antagonists - therapeutic use</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Prolactin - blood</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Schizophrenia - drug therapy</subject><subject>Schizophrenic Psychology</subject><issn>0893-133X</issn><issn>1740-634X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kL1PwzAQRy0EKqUwMSNlQCwoxRe7sT1CxZdUiQWkLshynDM1SpwQJwP960nViumG9-43PEIugc6BMnkX2nYOSrE5V0dkCoLTNGd8fUymVCqWAmPrU3IW4zelsBC5nJCJBLoQik7J5wMGdN56UyXoHNo-Jo1LgqlqdCNKzPBVY-hN75uQ-JAEHLqmwrb3No29KXzlt1gm0W78tmk3HQZvk3bUx6d4Tk6cqSJeHO6MfDw9vi9f0tXb8-vyfpVaBqxPiyJTpWE0o0KWlLM8sxnk6KhCnheGKwQpBTgFIHLFhJESHZeiKEQuUGZsRm72u23X_AwYe137aLGqTMBmiFrkFCRli1G83Yu2a2Ls0Om287XpfjVQvYupx5h6F1NzNdpXh9mhqLH8dw_1Rn594CZaU7nOBOvjv8YkZJAJ9gccyX3a</recordid><startdate>19930901</startdate><enddate>19930901</enddate><creator>RAPAPORT, M. H</creator><creator>WOLKOWITZ, O</creator><creator>KELSOE, J. R</creator><creator>PATO, C</creator><creator>KONICKI, P. E</creator><creator>PICKAR, D</creator><general>Nature Publishing</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19930901</creationdate><title>Beneficial effects of nalmefene augmentation in neuroleptic-stabilized schizophrenic patients</title><author>RAPAPORT, M. H ; WOLKOWITZ, O ; KELSOE, J. R ; PATO, C ; KONICKI, P. E ; PICKAR, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c313t-bb29da302078d04362c216ef09e46ba49e18871f91176937a88ef487bb767e823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Double-Blind Method</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Homovanillic Acid - blood</topic><topic>Humans</topic><topic>Hydrocortisone - blood</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Methoxyhydroxyphenylglycol - blood</topic><topic>Naltrexone - analogs & derivatives</topic><topic>Naltrexone - therapeutic use</topic><topic>Narcotic Antagonists - therapeutic use</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Prolactin - blood</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Schizophrenia - drug therapy</topic><topic>Schizophrenic Psychology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>RAPAPORT, M. H</creatorcontrib><creatorcontrib>WOLKOWITZ, O</creatorcontrib><creatorcontrib>KELSOE, J. R</creatorcontrib><creatorcontrib>PATO, C</creatorcontrib><creatorcontrib>KONICKI, P. E</creatorcontrib><creatorcontrib>PICKAR, D</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Neuropsychopharmacology (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>RAPAPORT, M. H</au><au>WOLKOWITZ, O</au><au>KELSOE, J. R</au><au>PATO, C</au><au>KONICKI, P. E</au><au>PICKAR, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Beneficial effects of nalmefene augmentation in neuroleptic-stabilized schizophrenic patients</atitle><jtitle>Neuropsychopharmacology (New York, N.Y.)</jtitle><addtitle>Neuropsychopharmacology</addtitle><date>1993-09-01</date><risdate>1993</risdate><volume>9</volume><issue>2</issue><spage>111</spage><epage>115</epage><pages>111-115</pages><issn>0893-133X</issn><eissn>1740-634X</eissn><coden>NEROEW</coden><abstract>It was postulated that chronic blockade of the opioid system in neuroleptic-stabilized schizophrenic patients would have a beneficial behavioral effect. Eleven neuroleptic-stabilized psychotic inpatients received augmentation with nalmefene for an average of 36.7 days in a double-blind placebo-controlled study. The patients exhibited significant reductions in Bunney-Hamburg psychosis ratings and the Brief Psychiatric Rating Scale thinking disturbance subscale during the augmentation period. This study presents preliminary data supporting the hypothesis that chronic augmentation of neuroleptic-stabilized schizophrenic patients with opiate antagonists is beneficial.</abstract><cop>New York, NY</cop><pub>Nature Publishing</pub><pmid>8105790</pmid><doi>10.1038/npp.1993.49</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0893-133X |
| ispartof | Neuropsychopharmacology (New York, N.Y.), 1993-09, Vol.9 (2), p.111-115 |
| issn | 0893-133X 1740-634X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_76018035 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; SpringerLink Journals - AutoHoldings |
| subjects | Adolescent Adult Antipsychotic Agents - therapeutic use Biological and medical sciences Double-Blind Method Drug Therapy, Combination Female Homovanillic Acid - blood Humans Hydrocortisone - blood Male Medical sciences Methoxyhydroxyphenylglycol - blood Naltrexone - analogs & derivatives Naltrexone - therapeutic use Narcotic Antagonists - therapeutic use Neuropharmacology Pharmacology. Drug treatments Prolactin - blood Psychiatric Status Rating Scales Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopharmacology Schizophrenia - drug therapy Schizophrenic Psychology |
| title | Beneficial effects of nalmefene augmentation in neuroleptic-stabilized schizophrenic patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T23%3A17%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Beneficial%20effects%20of%20nalmefene%20augmentation%20in%20neuroleptic-stabilized%20schizophrenic%20patients&rft.jtitle=Neuropsychopharmacology%20(New%20York,%20N.Y.)&rft.au=RAPAPORT,%20M.%20H&rft.date=1993-09-01&rft.volume=9&rft.issue=2&rft.spage=111&rft.epage=115&rft.pages=111-115&rft.issn=0893-133X&rft.eissn=1740-634X&rft.coden=NEROEW&rft_id=info:doi/10.1038/npp.1993.49&rft_dat=%3Cproquest_cross%3E76018035%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76018035&rft_id=info:pmid/8105790&rfr_iscdi=true |